Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth

Dexia Kong1,2*, Lijing Zhao2*, Yanwei Du2, Ping He1, Yabin Zou3, Luoluo Yang1, Liankun Sun2, Hebin Wang2, Deqi Xu4, Xiangwei Meng1, Xun Sun3

1Department of Gastroenterology, First Hospital of Jilin University, Changchun 130021, China; 2Department of Pathophysiology, School of Basic Medicine, Jilin University, Changchun 130021, China; 3Department of Pathology, First Hospital of Jilin University, Changchun 130021, China; 4New Vaccine National Engineering Research Center, Beijing Three-Room South Hospital, Beijing 100024, China. *Equal contributors.

Received August 31, 2014; Accepted October 16, 2014; Epub October 15, 2014; Published November 1, 2014

Abstract: GRIM-19 has been demonstrated as an important regulator for the normal tissue development. Recently, more evidences regarded GRIM-19 as the new tumor suppressor. However, the possible mechanisms underlying GRIM-19 suppressing cancer growth are unclear. In the present study, Paired hepatocellular carcinoma (HCC) and adjacent non-tumor liver tissues were obtained from 54 patients who underwent primary surgical HCC tissue resection. GRIM-19 protein expression in HCC tissues was performed by immunohistochemistry. Cells were transfected by lentiviruses plasmid expressing GRIM-19. RT-PCR and Western blot analyses were performed to confirm the expression of GRIM-19 mRNA or protein. Cell proliferation was assessed by MTT and FCM analyses. Mitochondrial membrane potential and apoptosis were respectively determined by using fluorescence microscopy and FCM analyses. AKT1, pAKT1, cyclinD1, CDK4, PCNA, Bax, Bcl-2, cleaved caspase-9, cleaved caspase-3, and cytochrome C were detected by Western blot and immunofluorescence. GRIM-19 protein expression was markedly lower in HCC than in paired adjacent non-tumor liver tissues. GRIM-19 overexpression in HCC cells significantly induced cell cycle arrest and enhanced apoptosis. We also found that AKT1 expression and phosphorylation were regulated by the expression of GRIM-19. Collectively, our study demonstrated that GRIM-19 overexpression suppressed HCC growth and downregulated AKT1 expression, suggesting that GRIM-19 might play a crucial role in hepatocarcinogenesis through negatively regulating the PI3K/AKT signaling pathway.

Keywords: GRIM-19, hepatocellular carcinoma, apoptosis, cell cycle, AKT1

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide but the second most frequent cause of cancer death [1]. Curative treatment options chiefly consist of surgical resection or liver transplantation [2]. Despite many scientific advances, HCC prognosis remains poor due to the absence of early disease symptoms, rapid tumor progression, and invasion-related spreading during early tumor stages [3]. Therefore, identifying potential biological markers for liver cancer occurrence and development is critical for developing new therapeutic strategies.

Accumulating evidence shows notable similarities between normal tissue development and tumorigenesis. For example, the Wnt/β pathway plays a critical role in regulating growth in normal liver development and is also a major mutation target in hepatocellular carcinoma [4]. P53, a tumor suppressor gene, is important for liver development, and its inactivation has been involved in HCC formation [5]. Based on these findings, genes that are involved in normal tissue developmental processes, if dysregulated, might contribute to the tumorigenesis. Gene associated with retinoic and interferon-induced mortality (GRIM-19; also called NDUFA13) was originally isolated as a growth suppressor by screening for an interferon (IFN)/all-trans retinoic acid (RA) combination-induced cell death in human cancer cell lines [6]. It does not belong to any of the known cell death gene categories,
such as the Bcl-xl, caspase, and death receptor families. GRIM-19 is a nuclear-encoded protein of mitochondrial respiratory chain complex I, which provides a link between the mitochondrion and its electron transport chain and apoptotic cell death [7, 8]. GRIM-19 is closely correlated with mitochondrial metabolism, cell growth, embryonic development, and innate immunity [8-11]. Homologous GRIM-19 gene deletion resulted in embryonic lethality by day 9.5, with the retarded growth and abnormal mitochondrial structure, morphology, and distribution exhibited in the blastocysts [12]. Recent studies reported that GRIM-19 protein expression was lost or severely repressed in numerous human cancers, including carcinomas of the kidney, colorectal, prostate, cervix, glioblastomas, lung, Hürthle cell thyroid, and breast [13-19]. These observations were further corroborated by upregulating STAT3, a multifaceted growth mediator in the cells, and specifically revealing the carcinoma tissues [20]. This suggests that GRIM-19 is not only essential for normal embryonic development, but also a key protein for tumorigenesis. However, the mechanisms underlying GRIM-19 inducing tumorigenesis are still poorly investigated.

In the present study, we examined the protein expression of GRIM-19 in human hepatocellular carcinoma and paired adjacent non-tumor liver tissues. Additionally, we investigated GRIM-19’s roles in human liver cancer cell lines and its possible mechanisms in tumorigenesis.

Materials and methods

HCC patient specimens and cell lines

HCC tissues and adjacent non-tumor liver tissues were collected from 54 HCC patients who underwent liver resection between June 2012 and June 2013 at the First Affiliated Hospital of Jilin University (Changchun, China). No patients had adjuvant therapies like chemotherapy or radiotherapy before surgery. This research was authorized by the Ethics Committee of the First Affiliated Hospital of Jilin University, and all patients signed an informed consent form. The human liver cell line SMMC-7721 was obtained from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China) and was cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum and 100 u/ml penicillin.

Plasmids, lentiviral particles, and establishment of stable cells

The GRIM-19 expression plasmid pIRES-Puro2-GRIM-19-Myc and the empty plasmid pIRES-Puro2-Myc were kindly provided by Professor Jiadi Hu (Greenebaum Cancer Center, Department of Microbiology and Immunology, Molecular Biology Program, University of Maryland School Medicine, Baltimore, Maryland). Lentiviral particle preparations were performed as previously described [21]. Briefly, GRIM-19 inserts were cloned into the XhoI and XbaI sites of pLVX-Puro (Clontech, Inc). HEK-293T cells were transfected with 5 µg of transfer vector (pLVX-Puro-GRIM-19-Myc), 3.75 µg of packaging plasmid (pCMV-dR8.2 dvpr), and 1.5 µg of envelope plasmid (pVSV-G) (Addgene, Inc.) using Lipofectamine-Plus reagent (Invitrogen, Inc.) for 6 h in serum-free medium. Cells were then fed with regular growth medium. Viral particles from the growth medium were collected from 48-96 h after transfection. The medium was centrifuged to remove debris and filtered through a 0.45 µm filter. SMMC-7721 cells were transfected with the viral titers and then selected by puromycin. After 2 weeks, the number of infectious virus particles was estimated based on the number of puromycin-resistant colonies formed.

Immunohistochemistry

A total of 54 hepatocellular carcinoma tumors and adjacent non-tumor liver tissues were used to determine GRIM-19 expression. All samples were fixed with 4% formaldehyde, dehydrated, and cut into 3 µm serial sections. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide in methanol for 15 min. The samples were washed twice with PBS and incubated with the appropriate primary antibody dilutions (1:300) at 4°C overnight. Mouse anti-human GRIM-19 antibody (Abcam, Hong Kong) was utilized. Samples were washed twice in PBS and incubated with the corresponding secondary antibody for 25 min at room temperature. Then, antigen-antibody complexes were washed with PBS and incubated for 1 min with high-sensitivity DAB (St. Louis, MO, USA) substrate. Finally, the sections were counterstained with hematoxylin.
and dehydrated, mounted, and examined by light microscopy. Briefly, the percentage of cells positively stained in each section was categorized as follows: negative (samples with > 5% positive cells), low (5-25% positive cells), moderate (25-50% positive cells), and strong (50-100% positive cells) were considered as -, +, ++, and ++++, respectively, for these analyses.

**Semi-quantitative RT-PCR**

Total RNA was extracted from the cells using a Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. First-strand cDNA was synthesized by reverse transcription of 5 µg total RNA using a Takara RNA PCR Kit (TaKaRa, Japan). Primers used in semiquantitation RT-PCR were as follows: β-actin sense, 5'-ATATCGCTGCGCTGGTCGTC-3' and antisense, 5'-AGGATGGCGTGAGGGAGAGC-3'; GRIM-19 sense, 5'-AGTATGGCGGCGTCAAAGGTG-3' and antisense, 5'-TTTTTTTCCA-GGTCTGC-AGAGC-3'. The PCR products were separated by electrophoresis on 1% agarose gels containing ethidium bromide and visualized by a GIs Gelatun imaging system (Tanon, Shanghai, China). Absolute gene transcription was compared to that of β-actin.

**Western blot assay**

We performed western blot analysis to determine protein level changes. The lysates were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA, USA). The following antibodies were used: monoclonal cyclinD1, Akt1, pAkt1, GRIM-19, and proliferating cell nuclear antigen (PCNA), all of which were purchased from Abcam (California, USA). Bax, Bcl-2, cleaved caspase-9, and β-actin were purchased from Santa Cruz Biotechnology, and cleaved caspase-3, cytochrome C, and CDK4 were purchased from Cell Signaling Technology (Boston, MA, USA).

**Cell proliferation assay**

In 96-well plates 1.5×10³ cells per well were seeded and incubated for the indicated period of time at 37°C. Then, cell growth was measured using the 4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT). The cells were harvested and incubated with DMSO for 30 min, and absorbance was measured using a plate reader in 570 nm of wavelength.

**Flow cytometry analysis**

Treated cells, including adherent and non-adherent cells, were trypsinized and centrifuged, washed, and stained using the Annexin-V-FITC Apoptosis Detection Kit (Beyotime, Shanghai, China) and Propidium Iodide (Beyotime, Shanghai, China). The samples were then analyzed for apoptosis and cell cycle by a FACScanflow cytometer (Becton Dickinson, Franklin Lakes, NJ).

**Mitochondrial membrane potential (Δψm) assay**

Mitochondrial stability was assessed using a mitochondrial membrane potential assay kit with JC-1 (5,5’;6,6-tetrachloro-1,1’3,3’-tetraethylbenzimidazolocarbocyanine iodide). Stable cells were cultured in 12-well plates. After 24 h treatment, the cells were incubated with 1 ml JC-1 fluorescent dye for 30 min in the dark at 37°C. Then, the cells were washed slowly twice with JC-1 dyeing buffer. The mitochondrial membrane potential was imaged using fluorescence microscope (Olympus, Tokyo, Japan) at 550 nm excitation and 570 nm emissions.

**Immunofluorescence**

Cells were cultured on sterile cover glass (Fisher Scientific, Inc.) in a 24-well tissue culture plate for 24 h before staining. They were fixed for 15 min using 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 in PBS, and blocked in 5% BSA. Primary antibodies were diluted in PBS containing 3% BSA (1:100) and incubated for 24 h at room temperature. After washing with PBS, cells were incubated with Alexa Fluor 555-labeled secondary antibodies (diluted 1:400 in blocking buffer) for 1 h and washed with PBS again. Thereafter, nuclei from the samples were counterstained with Hoechst 33258 (Invitrogen, Carlsbad, CA, USA) and inspected with a confocal microscope (Olympus, Tokyo, Japan).

**Statistical analysis**

All experiments were performed at least in triplicate. The data are expressed as the mean values±standard deviation (SD). Statistical analysis was performed using the SPSS19.0 statistical software. Comparisons between treatments were made using a paired Student’s t-test, or one-way ANOVA for multiple group
GRIM-19 overexpression suppresses hepatocellular carcinoma

Table 1. A summary of GRIM-19 expression in all 54 HCC tissues and adjacent non-tumor liver tissues

<table>
<thead>
<tr>
<th></th>
<th>-</th>
<th>+</th>
<th>++</th>
<th>+++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular carcinoma tissues (case)</td>
<td>24</td>
<td>30</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Paried adjacent non-tumor tissues (case)</td>
<td>0</td>
<td>6</td>
<td>29</td>
<td>19</td>
</tr>
</tbody>
</table>

comparisons. P < 0.05 was considered statistically significant.

Results

Immunohistochemical analysis of GRIM-19 expression in HCC tissues and adjacent non-tumor liver tissues

To investigate the profile of GRIM-19 in HCC tissue, we evaluated the protein expression in HCC tissues and adjacent non-tumor liver tissues using immunohistochemistry. GRIM-19 protein was found to be highly expressed in adjacent non-tumor liver tissues and decreased in HCC tissues (Figure 1). The case of negative GRIM-19 expression in adjacent non-tumor liver tissues was 0 and that of HCC tissues was 24; the case of low GRIM-19 expression in adjacent non-tumor liver tissues was 6 and that of HCC tissues was 30; the case of moderate GRIM-19 expression in adjacent non-tumor liver tissues was 29 and that of HCC tissues was 0; and the case of strong GRIM-19 expression in adjacent non-tumor liver tissues was 19 and that of HCC tissues was 0, as shown in Table 1.

Figure 1. GRIM-19 expression in adjacent non-tumor liver tissues (A) and HCC tissues (B). Representative pictures of 54 hepatocellular carcinoma tumor samples and paired adjacent non-tumor liver tissues are shown. Original magnification: 200×.

GRIM-19 overexpression could inhibit tumor cell proliferation and induce G1/S cell cycle arrest and apoptosis in SMMC-7721 cells

Firstly, the stable cell line expressing wild-type GRIM-19 was established by transfecting lentiviral particles to hepatocellular cell line SMMC-7721 cells. It is demonstrated that GRIM-19 was effectively overexpressed in the lentiviral particles expressing wild-type GRIM-19 transfected cells (GRIM-19) compared to cells transfected with empty vector (EV). Furthermore, the mRNA and protein expression of GRIM-19 was significantly increased in the lentiviral particles expressing wild-type GRIM-19 transfected SMMC-7721 cells (Figure 2A, 2B).

Next, we analyzed whether elevated GRIM-19 expression would affect liver cancer cell proliferation, cell cycle or apoptosis. As shown in Figure 2C, overexpression of GRIM-19 markedly inhibited the SMMC-7721 cell growth compared to the same cells transfected with the empty vector. Meanwhile, we examined GRIM-19’s effects on the cell cycle distribution in SMMC-7721 using flow cytometry (FCM). In the SMMC-7721 cells transfected with GRIM-19, the percentage of cells in the G1 phase and the ratio of G1 cells to S phase cells were increased compared to the control (Figure 2D, 2E). Then, we investigated mitochondrial membrane potential (Δψm) with JC-1 staining, because
GRIM-19 overexpression suppresses hepatocellular carcinoma

Figure 2. GRIM-19 overexpression controls cell proliferation, induces G1/S arrest, and enhances apoptosis in SMMC-7721 cells. SMMC-7721 cells were transfected with the lentiviral particles expressing wild-type GRIM-19 (GRIM-19) or an empty vector (EV); A. RT-PCR analysis of GRIM-19 mRNA overexpression; B. Western blot analysis of GRIM-19 protein overexpression; C. MTT assay showed GRIM-19 overexpression controls cell proliferation compared with the control; D. FCM raw data with PI staining for cell cycle arrest; E. Values represent the percentage of cells in each cell cycle phase; F. JC-1 staining evaluated exogenous GRIM-19’s effect on mitochondrial membrane potential. Red fluorescence is visible in cellular areas with high mitochondrial membrane potential, while green fluorescence of JC-1 monomer is present in cellular areas with low mitochondrial potential. Original magnification 400×; G. Representative FCM raw data with Annexin-V-FITC and PI staining for detecting cell death; H. Results from the different treatment conditions are presented as averages from the FCM assays. Data represent the mean±SD for three replicated experiments. *P < 0.05. Representative images of three separate experiments are shown in the figure.

loss of mitochondrial membrane potential was an important event during the mitochondrial-mediated apoptosis. Fluorescence from red to green was observed in response to GRIM-19 and EV treatment, respectively (Figure 2F). To quantify apoptosis, flow cytometry analysis of Annexin-V-FITC and propidium iodide staining were used. An increase in the apoptotic cell population in SMMC-7721 cells treated with ectopic GRIM-19 was observed (Figure 2G, 2H). Taken together, these results suggest that overexpression of GRIM-19 suppresses cell proliferation, induces G1/S cell cycle arrest, and increases apoptosis in SMMC-7721 cells.

Exogenous GRIM-19 induced cell cycle arrest by altering the cell cycle protein levels in SMMC-7721 cells

To elucidate the mechanism underlying the exogenous GRIM-19-mediated cell cycle arrest in HCC cells, various cell cycle regulatory proteins were examined by western blot analysis. The cells transfected with exogenous GRIM-19
showed a significant increase in G1 arrested cells, measured by the downregulation of cyclin D1, CDK4, and PCNA expression (Figure 3A). These results were supported by immunofluorescence analysis for cyclinD1, CDK4, and PCNA. The fluorescence intensity of these cell cycle proteins was significantly decreased in the SMMC-7721 cells transfected with GRIM-19 compared to control groups, respectively (Figure 3B), suggesting that GRIM-19 overex-
GRIM-19 overexpression suppresses hepatocellular carcinoma

Expression efficiently induces G1/S arrest through lessening cyclinD1, CDK4, and PCNA protein expression.

**Exogenous GRIM-19 enhanced HCC cell apoptosis by activating the mitochondrial apoptosis pathway**

To determine the mechanism of enhanced HCC cell apoptosis by exogenous GRIM-19, we investigated the mitochondrial apoptosis pathway’s influence. We next analyzed the Bcl-2 family proteins, including the pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins that regulated mitochondrial membrane potential and cytochrome C released from the mitochondrial inner membrane. We evaluated caspase-3 and caspase-9 expression by Western blot assay in the SMMC-7721 cells treated with lentiviral particles expressing wild-type GRIM-19. The cells transfected with the empty vector were used as a negative control. As shown in **Figure 4A**, exogenous GRIM-19 treatment significantly increased pro-apoptotic protein Bax expression and downregulated anti-apoptotic protein Bcl-2 expression in the SMMC-7721 cells. On the other hand, cytochrome C, cleaved caspase-3, and cleaved caspase-9 expression were upregulated. In accordance with these results, the cells transfected with exogenous GRIM-19 tended to have stronger staining for Bax, cytochrome C, cleaved caspase-3, and cleaved caspase-9 and weaker staining for Bcl-2 compared to the negative control (**Figure 4B**). These results reveal the enhanced HCC cell apoptosis by exogenous GRIM-19 is at least mediated by activating the mitochondrial apoptosis pathway.

**Figure 4.** Exogenous GRIM-19 activates the mitochondrial apoptosis pathway to accelerate HCC cell apoptosis. A. Western blot assay for protein expression of Bax, Bcl-2, cytochrome C, cleaved caspase-3, and cleaved caspase-9 in cells transfected with exogenous GRIM-19 or the empty vector. *P < 0.05; B. The above-mentioned transfected HCC cells were immunostained for Bax, Bcl-2, cytochrome C, cleaved caspase-3, and cleaved caspase-9 with corresponding antibodies. Representative merged images with Hoechst 33258 labeled DNA are shown (400x magnifications).
GRIM-19 overexpression suppresses hepatocellular carcinoma

The PI3K/AKT pathway plays a key role in hepatocarcinogenesis. To further research the possible mechanism involved in GRIM-19-mediated growth inhibition in SMMC-7721 cells, we surveyed GRIM-19’s effects on AKT1 protein expression and phosphorylation that is a key process in the above signaling pathway. As shown in Figure 5A, Western blot analysis revealed that exogenous GRIM-19 significantly lessened AKT1/pAKT1 expression. Immunofluorescence analysis showed AKT1 downregulation in the SMMC-7721 cells transfected with exogenous GRIM-19 compared to cells transfected with the empty vector (Figure 5B). These findings suggest that GRIM-19 restricts hepatocellular carcinoma cell growth by potentially negatively regulating the PI3K/AKT signaling pathway.

Discussion

Recent Studies have shown that the main reasons for malignant tumors are closely related to genes that impact cellular differentiation, developmental processes, and senescence during normal growth [22]. More and more genes essential for normal tissues or organs growth and development have been identified being involved in hepatocellular carcinoma [23, 24]. GRIM-19 gene is a novel gene essential for development. Our study showed GRIM-19 expression was decreased in most of the HCC samples in contrast to adjacent non-tumor liver tissues, which is in agreement with previous reports [25]. These results indicated that GRIM-19 might be involved in hepatocellular carcinoma pathogenesis. It has been reported that tumorigenesis was closely associated with GRIM-19 gene mutation or dysfunction [26]. Nevertheless, the exact mechanisms which cause GRIM-19 inactivation in HCC remain unknown.
GRIM-19 overexpression suppresses hepatocellular carcinoma

More and more studies highlight that GRIM-19’s function as a tumor suppressor seems to occur at multiple levels. In previous study, Peng et al. proved that GRIM-19 could induce G1/S arrest of breast cancer cells by downregulation of CDK4 and cyclinD1 [27]. GRIM-19 has also been found to suppress cell growth in lung cancer cells and glioma cells via the stat3-associated signaling pathway, accompanied by upregulation of Bax and downregulation of Bcl-2 [18, 19]. Depleting GRIM-19 accelerated hepatocellular carcinoma invasion [28]. However, we have gained insight into how GRIM-19 might control liver cancer growth. In this study, overexpressing GRIM-19 resulted in a significant decrease in SMMC-7721 cell growth. Cell cycle regulation is an important mechanism of normal cell growth. Normal cell progression from G1-S-G2-M-G0 during the division cycle is tightly controlled by the protein kinase activity of a class of serine-threonine kinases (CDK). CDK4, called the cyclin-dependent kinases, and cyclinD1, known as cyclins, are important factors during normal cell progression from G1-S-G2-M-G0 [29-31]. PCNA is a nuclear protein that is expressed in G-M phases of the cell cycle. Our results showed GRIM-19 overexpression efficiently induced G1/S arrest by lessening cyclinD1, CDK4, and PCNA protein expression in SMMC-7721 cells. These results were similar in MCF-7 cells and HeLa cells [27, 32]. G1 arrest can prevent damaged DNA replication and is therefore helpful in limiting uncontrolled cancer cell proliferation.

Additionally, a previous study demonstrated that moderate GRIM-19 levels caused cycle arrest and high expression of GRIM-19 induced apoptosis in MCF-7 cells [6]. Moreover, apoptosis reportedly plays an important role during malignant normal cell growth transformation [33]. The relative balance of various pro-apoptotic (Bax, Bad) and anti-apoptotic (Bcl-2, Bcl-XL, Bcl-w, and Mcl-1) Bcl-2 family members is a critical cellular homeostasis determinant [34, 35]. The anti-apoptotic Bcl-2 proteins interfere with engaging the mitochondrial apoptotic machinery by inhibiting Bax and Bak oligomerization [36]. Bax is translocated into mitochondria upon apoptosis induction. After translocation, Bax forms large oligomers, which insert into mitochondrial membranes and lead to cytochrome C release and cytotoxic activities. MMP’s collapse can initiate molecules being released from the space between the outer and inner mitochondrial membranes into the cyto-
sol, which triggers the caspase cascade and other apoptotic processes [37]. In our study, we revealed that GRIM-19 overexpression promoted apoptosis by increasing the Bax/Bcl-2 ratio and cytochrome C, cleaved caspase-3, and cleaved caspase-9 protein to activate the intrinsic mitochondrial pathway, in addition to GRIM-19 inducing G1/S arrest. These discoveries imply that GRIM-19 dysregulation may disrupt the balance between proliferation and apoptosis and, as such, may represent an important pathogenic step in hepatocellular carcinoma development.

The PI3/AKT signaling pathway has been found to play important roles in regulating key cellular processes such as survival, proliferation, and differentiation [38]. AKT1 is a key molecule in the above signaling pathway. It is generally believed that AKT1 activation contributes to the development and progression of many types of cancer, including liver cancer. Phosphorylation on Ser473 is required for full activity. Previous studies have shown that AKT1 activation can promote cell survival, accelerate cell cycle progression, and inhibit cell apoptosis by regulating its downstream target genes such as CDK4, cyclinD1, Bcl-2, and Bax [39, 40]. Interestingly, a recent study demonstrated that pAKT1 was significantly expressed in HCC specimens [41]. Moreover, study has shown that GRIM-19 appears lower expression in human liver cancer tissues in comparison to the normal liver tissues [25]. These results suggest there may be some kind of relationship between GRIM-19 inactivation and AKT1 activation. GRIM-19 may control AKT1 expression and phosphorylation and then regulate cell cycle progression and cell apoptosis. To verify the hypothesis and further research the possible mechanism involved in GRIM-19-mediated growth inhibition, we surveyed its effects on AKT1/pAKT1 protein in SMMC-7721 cells. The results from this study demonstrate that exogenous GRIM-19 weakens AKT1 expression and phosphorylation, implying that GRIM-19 may negatively regulate PI3K/AKT signaling pathway to inhibit HCC growth.

In summary, we have shown that GRIM-19 downregulation occurs in hepatocellular cancer samples and that GRIM-19 suppresses liver cancer cell growth by inducing cell cycle arrest and promoting apoptosis. Furthermore, for the first time, we have provided evidence that GRIM-19 inhibited AKT1 expression and phos-
phorylation, which might alleviated the PI3K/AKT signaling pathway and then control liver cancer cell growth. There may be a couple of limitations in the present studies. For instance, since we have used only SMMC-72 cells in the present study, whether these results are also applicable to other liver cancer cell lines or other tumor cells remains unaddressed. How GRIM-19 affects AKT1 expression and phosphorylation remains unclear. Therefore, these interesting issues will be continually investigated in future studies. Considering GRIM-19’s role in hepatocarcinogenesis, GRIM-19 recovery may be a novel and potential strategy to treat hepatocellular cancer.

Acknowledgements

This work was funded by the National Natural Science Foundation of China (No. 81270529) and the Science & Technology Development Planning Project of Jilin Province (No. 20120953 and No. 20140414006GH).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xiangwei Meng or Xun Sun, Department of Gastroenterology or Pathology, First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China. Tel: (86) 43185619183; Fax: (86) 431-85619183; E-mail: xiangweimeng2003@163.com (XWM); Tel: (86)-18642802811; Fax: (86) 431-85619183; E-mail: 36329734@qq.com (XS)

References

GRIM-19 overexpression suppresses hepatocellular carcinoma


